Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000 Jul;130(5):963-74.
doi: 10.1038/sj.bjp.0703393.

Endothelial dysfunction in diabetes

A S De Vriese  1 , T J Verbeuren, J Van de Voorde, N H Lameire, P M Vanhoutte
Affiliations
Review

Endothelial dysfunction in diabetes

A S De Vriese et al. Br J Pharmacol. 2000 Jul.

Abstract

Endothelial dysfunction plays a key role in the pathogenesis of diabetic vascular disease. The endothelium controls the tone of the underlying vascular smooth muscle through the production of vasodilator mediators. The endothelium-derived relaxing factors (EDRF) comprise nitric oxide (NO), prostacyclin, and a still elusive endothelium-derived hyperpolarizing factor (EDHF). Impaired endothelium-dependent vasodilation has been demonstrated in various vascular beds of different animal models of diabetes and in humans with type 1 and 2 diabetes. Several mechanisms of endothelial dysfunction have been reported, including impaired signal transduction or substrate availibility, impaired release of EDRF, increased destruction of EDRF, enhanced release of endothelium-derived constricting factors and decreased sensitivity of the vascular smooth muscle to EDRF. The principal mediators of hyperglycaemia-induced endothelial dysfunction may be activation of protein kinase C, increased activity of the polyol pathway, non-enzymatic glycation and oxidative stress. Correction of these pathways, as well as administration of ACE inhibitors and folate, has been shown to improve endothelium-dependent vasodilation in diabetes. Since the mechanisms of endothelial dysfunction appear to differ according to the diabetic model and the vascular bed under study, it is important to select clinically relevant models for future research of endothelial dysfunction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of endothelial dysfunction in diabetes. R, receptor; EDRF, endothelium-derived relaxing factor; EDHF, endothelium-derived hyperpolarizing factor; PGI2, prostacyclin; EDCF, endothelium-derived constricting factors; TXA2, thromboxane A2; PGH2, prostaglandin H2; 5-HETE, 5-hydroxyeicosatetraenoic acid; TP, prostanoid TP receptor; O2.−, superoxide anion.
Figure 2
Figure 2
Outline and interactions of hyperglycaemia-induced metabolic pathways potentially involved in the pathophysiology of endothelial dysfunction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. ANDERSON T.J. Assessment and treatment of endothelial dysfunction in humans. J. Am. Coll. Cardiol. 1999;34:631–638. - PubMed
    1. ANGULO J., RODRIGUEZ-MANAS L., PEIRO C., NEIRA M., MARIN J., SANCHEZ-FERRER C.F. Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. Naunyn Schmiedeberg's Arch. Pharmacol. 1998;358:529–537. - PubMed
    1. ARCARO G., ZENERE B.M., SAGGIANI F., ZENTI M.G., MONAUNI T., LECHI A., MUGGEO M., BONADONNA R.C. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care. 1999;22:1536–1542. - PubMed
    1. BAYNES J.W., THORPE S.R. Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes. 1999;48:1–9. - PubMed
    1. BHARDWAJ R., MOORE P.K. Increased vasodilator response to acetylcholine of renal blood vessels from diabetic rats. J. Pharm. Pharmacol. 1988;40:739–742. - PubMed